RxDoctor Payments DataLook up a doctor →

Taral Patel, MD

Interventional Cardiology · Scottsdale, AZNPI 1730111642

Payments from drug & device makers

$376,784in general payments, 2019–2025

Across 535 payments — averaging $704.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$108K
  • Angiodynamics, Inc.$103K
  • Boston Scientific$88K
  • Abbott$43K
  • Cardiovascular Systems Inc.$16K
  • Teleflex LLC$9K
  • plus $10K from 32 others

What the payments were for

  • Consulting fees$59,78335%
  • Speaking & faculty fees$74,28043%
  • Travel & lodging$17,40610%
  • Food & beverage$16,47610%
  • Education$3,2002%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$376,784 in reported general payments places this provider in the 90th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$330,817
Medicare patients
697
Services billed
3,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$226,547
XareltoRivaroxaban54$57,562
EntrestoSacubitril/Valsartan21$30,839
JardianceEmpagliflozin28$28,303
Repatha SureclickEvolocumab33$26,081
BrilintaTicagrelor27$25,556
FarxigaDapagliflozin Propanediol11$6,753
Metoprolol Succinate284$3,652
ClopidogrelClopidogrel Bisulfate267$3,395
Rosuvastatin Calcium233$3,138
Atorvastatin Calcium337$3,125
Flecainide Acetate28$1,909
Losartan Potassium188$1,713
Midodrine Hcl11$1,345
Ezetimibe83$1,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$203$226,547179 claims
Johnson & JohnsonXarelto$813$57,56254 claims
AstraZenecaBrilinta, Farxiga$129$32,30938 claims
NovartisEntresto$458$30,83921 claims
Boehringer IngelheimJardiance$16$28,30328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →